美国食品和药物管理局对三号类型高氏病的Sanofi毒剂给予突破性地位. FDA gives breakthrough status to Sanofi’s venglustat for rare type 3 Gaucher disease.

美国FDA已授予Sanofi的实验药物venglustat突破性治疗指标,用于治疗3型高氏病,这种罕见的遗传疾病会导致器官损伤和由于脂质积累而引起的神经问题. The U.S. FDA has granted breakthrough therapy designation to Sanofi’s experimental drug venglustat for treating type 3 Gaucher disease, a rare genetic disorder causing organ damage and neurological issues due to lipid buildup. 认可格拉斯塔特有潜力显著改善治疗,针对疾病的代谢根源. The status recognizes venglustat’s potential to significantly improve treatment, targeting the disease’s metabolic root cause. 虽然早期数据有希望,但该药物仍在研究中,尚未获得批准. While early data is promising, the drug remains under investigation and is not yet approved. 为了评估其安全性和有效性,正在进行进一步的临床试验. Further clinical trials are ongoing to assess its safety and effectiveness.